{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"4"}]}],"title":"On-treatment deaths"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"13"}]}],"title":"Post-treatment deaths"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"17"}]}],"title":"All deaths"}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"20"}],"units":"Participants"}],"description":"On treatment deaths were collected from FPFT up to 30 days after study drug discontinuation, for a maximum duration with dabrafenib and trametinib of 81 months (study treatment with dabrafenib and trametinib ranged from 0.3 to 80.0 months).\n\nDeaths post treatment survival follow up were collected after the on- treatment period, up to approximately 9 years. Patients who didn't die during the on-treatment period and had not stopped study participation at the time of data cut-off (end of study) were censored.","groups":[{"description":"Participants who have relapsed or progressed after receiving at least one line of prior anti-cancer therapy for metastatic disease received dabrafenib 150 mg BID. It was continued until disease progression or death or unacceptable AEs or investigator discretion to discontinue or decision to crossover from monotherapy to combination therapy.","id":"OG000","title":"Cohort A (Dabrafenib Monotherapy)"},{"description":"Participants who had received 1-3 prior lines of systemic anti-cancer therapies for advanced stage/metastatic disease received Dabrafenib 150 mg BID and Trametinib 2 mg once daily (OD). Treatment continued until disease progression, death, or unacceptable AEs or investigator discretion to discontinue.","id":"OG001","title":"Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD"},{"description":"Participants who had not received any prior systemic anti-cancer for metastatic disease therapies were given Dabrafenib 150 mg BID and Trametinib 2 mg OD. Treatment continued until disease progression, death, or unacceptable AEs or at investigator discretion to discontinue.","id":"OG002","title":"Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD"},{"description":"Crossover - Double Combination (Dabrafenib+Trametinib): Participants received Dabrafenib 150 mg BID in combination with Trametinib 2 mg once daily and continued treatment until disease progression, death, or unacceptable adverse event.","id":"OG003","title":"Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Clinical database population; all treated patients.","reportingStatus":"POSTED","timeFrame":"up to 81 months (study treatment with dabrafenib and trametinib), up to approximately 9 years (study duration)","title":"All Collected Deaths","type":"POST_HOC","unitOfMeasure":"Participants"}